|
Latest Paper:
Curr Med Res Opin. 2012 May 15;:
22587482
ABSTRACT Background: This brief review presents a comprehensive evaluation of valproate induced encepalopathy (VHE) and also discusses potential mechanisms of the condition. Scope: Sodium Valproate (VPA) is an effective antiepileptic drug used in neurology as well as in psychiatry, in adults and children. VHE requires early diagnosis and management. Focused research efforts in understanding the condition will help decrease its incidence. Delay in recognition of VHE can result in the development of potentially life-threatening complications. Findings: Management options are described. Since VPA frequently causes a modest rise in plasma ammonia levels which is asymptomatic, it is important to recognize the symptoms of VHE promptly and to correlate them with the plasma ammonia levels. Conclusions: Although there are several case reports on VHE, this review is a comprehensive evaluation of its causes and potential mechanisms. Rapid diagnosis and management will help in reducing VHE-related morbidity.
Stem Cells Dev. 2012 May 1;:
22548356
Amit Deshpande,
Omar Khalid,
Jeffrey Jin-Hyung Kim,
Yong Kim,
Anne Lindgren,
Amander Clark,
David Wong
UCLA, Dentistry, Los Angeles, California, United States; ADeshpan@alumni.uconn.edu.
In this study we present data to support the role for Cdk2ap2 in regulating self-renewal of mouse embryonic stem cells (mESC) under permissive conditions, and cell survival during differentiation of the mESC into terminally differentiated cell types. To understand the function of Cdk2ap2 during early development we generated mESC with homozygous disruption of the endogenous Cdk2ap2 locus (Cdk2ap2tr/tr). The Cdk2ap2tr/tr mESC, when grown in complete growth medium containing LIF, showed an early differentiation phenotype characterized by flattened colonies and a distinct intercellular boundary. We also observed downregulation of Nanog and upregulation in markers of mesoderm and endoderm differentiation including, Brachyury (T), Afp, and S100a, when compared to Wt mESC. Cdk2ap2tr/tr mESC were able to form Embryoid Bodies (EBs) however those EBs were unhealthy and had an increased level of apoptosis. Furthermore, Cdk2ap2tr/tr mESC were unable to form teratomas in SCID mice. Cdk2ap2 under normal conditions has a biphasic expression suggesting regulatory roles in early vs. late stem cell differentiation. These data begin to add to our understanding of how Cdk2ap2 may be involved in the regulation of self-renewal of stem cells during early embryogenesis.
Nitin K Hingankar,
Smita R Thorat,
Alaka Deshpande,
S Rajasekaran,
C Chandrasekar,
Suria Kumar,
Padmini Srikantiah,
Devidas N Chaturbhuj,
Sharda R Datkar,
Pravin S Deshmukh,
Smita S Kulkarni,
Suvarna Sane,
D C S Reddy,
Renu Garg,
Michael R Jordan,
Sandhya Kabra,
Srikanth P Tripathy,
Ramesh S Paranjape
National AIDS Research Institute, Pune.
Human immunodeficiency virus drug resistance (HIVDR) in cohorts of patients initiating antiretroviral therapy (ART) at clinics in Chennai and Mumbai, India, was assessed following World Health Organization (WHO) guidelines. Twelve months after ART initiation, 75% and 64.6% of participants at the Chennai and Mumbai clinics, respectively, achieved viral load suppression of <1000 copies/mL (HIVDR prevention). HIVDR at initiation of ART (P <.05) and 12-month CD4 cell counts <200 cells/μL (P <.05) were associated with HIVDR at 12 months. HIVDR prevention exceeded WHO guidelines (≥70%) at the Chennai clinic but was below the target in Mumbai due to high rates of loss to follow-up. Findings highlight the need for defaulter tracing and scale-up of routine viral load testing to identify patients failing first-line ART.
Herve Jacques Fleury,
Delphine Anquetil,
Alaka Deshpande,
Drissa Zongo,
Laurent Lebihan,
Patricia Pinson
universite Bordeaux 2, Virologie EA 2968, 146 rue Leo Saignat, Bordeaux, France, 33076, 00 33 5 57 57 13 63, 00 33 5 56 99 11 40; herve.fleury@viro.u-bordeaux2.fr.
We analyzed subtype C HIV-1 isolates from patients at failure of a regimen including Nevirapine or Efavirenz for their susceptibility or resistance to Etravirine according to the ANRS and Stanford algorithms. Statistical analysis showed a consensus that more than 45% of these viral strains are potentially resistant to Etravirine.
V Balasubramanian,
S Solapure,
S Gaonkar,
Kn Mahesh Kumar,
Rk Shandil,
Abhijeet Deshpande,
Naveen Kumar,
Kg Viswas,
Vijender Panduga,
Jitendar Reddy,
Samit Ganguly,
A Louie,
G L Drusano
AstraZeneca India Pvt. Ltd., Hebbal, Bellary Road, Bangalore 560024, India.
Moxifloxacin plus rifampin was evaluated in a murine model of Mycobacterium tuberculosis pulmonary infection to determine whether the finding of antagonism documented in the hollow fiber infection model could be recapitulated in vivo. Colony counts were followed in a no-treatment control group, moxifloxacin and rifampin monotherapy groups, and the combination of the two agents. Following 18 days of once-daily oral administration to mice infected with M tuberculosis, there was a reduction in the plasma exposure to rifampin, which decreased further when co-administered with moxifloxacin. Pharmacodynamic analysis demonstrated a mild antagonistic interaction between moxifloxacin and rifampin with respect to cell kill in the mouse model for tuberculosis No emergence of resistance was noted over 28 days of therapy, even with monotherapy. This is true even though one of the agents in the combination (moxifloxacin) induces error-prone replication. The previously noted antagonism with respect to cell kill shown in the hollow fiber infection model was recapitulated in the murine TB lung model, although to a lesser extent.
Brigham and Women's Hospital and Harvard Medical School, Department of Medicine , Boston, MA 02215 , USA.
Introduction: Myeloproliferative neoplasms (MPNs) are a group of stem cell diseases, including polycythemia vera, essential thrombocythemia and primary myelofibrosis. Currently, there is no curative therapy for these diseases other than bone marrow transplant; therefore there is an apparent need for palliative treatment. MPNs are frequently associated with activating mutations in JAK2; small-molecule drugs targeting this molecule have entered clinical trials. Areas covered: In this review novel JAK2 inhibitors are discussed and alternative approaches to inhibiting their transforming potential are highlighted. Current clinical approaches do not only aim at blocking JAK2 activity, but also at reducing its stability and expression are highlighted, including inhibition of heat shock protein 90 (HSP90) and deacetylases (DAC) have the potential to significantly enhance the efficacy of JAK2 inhibitors. Expert opinion: Preliminary results from clinical trials indicate the feasibility and efficacy of JAK2-targeted approaches. However, JAK2 inhibitor treatment is limited by dose-dependent toxicity and combination treatment might be required. The discovery of JAK2 mutations that cause secondary resistance in vitro would further highlight the need for the development of next-generation JAK2 inhibitors and novel synergistic approaches.
Cleveland Clinic, Cleveland, Ohio.
Maharashtra Pollution Control Board, Mumbai, India. ajaydeshpande1@rediffmail.com
The unwanted sound is referred to as noise. Prolonged exposure to such noise has ill effects on humans as well as on animals. Also, it is one of the environmental pollutants. The sources of noise pollution are present well within our houses. External factors add to additional noise pollution. It has direct impact on the hearing capacity. Apart from this, it also has adverse effects on the mental state of a human being. Noise pollution is a major problem during various festivals. The present study deals with the monitoring of noise levels at different locations during Ganesh festival. The monitoring was done at commercial, residential and silence zones. The study revealed that the noise level exceeded the prescribed limits at all the locations. Also, the restriction of 10 p.m. for noise was not followed by the general public.
A Adare,
S Afanasiev,
C Aidala,
N N Ajitanand,
Y Akiba,
H Al-Bataineh,
J Alexander,
K Aoki,
Y Aramaki,
E T Atomssa,
R Averbeck,
T C Awes,
B Azmoun,
V Babintsev,
M Bai,
G Baksay,
L Baksay,
K N Barish,
B Bassalleck,
A T Basye,
S Bathe,
V Baublis,
C Baumann,
A Bazilevsky,
S Belikov,
R Belmont,
R Bennett,
A Berdnikov,
Y Berdnikov,
A A Bickley,
J S Bok,
K Boyle,
M L Brooks,
H Buesching,
V Bumazhnov,
G Bunce,
S Butsyk,
C M Camacho,
S Campbell,
C-H Chen,
C Y Chi,
M Chiu,
I J Choi,
R K Choudhury,
P Christiansen,
T Chujo,
P Chung,
O Chvala,
V Cianciolo,
Z Citron,
B A Cole,
M Connors,
P Constantin,
M Csanád,
T Csörgő,
T Dahms,
S Dairaku,
I Danchev,
K Das,
A Datta,
G David,
A Denisov,
A Deshpande,
E J Desmond,
O Dietzsch,
A Dion,
M Donadelli,
O Drapier,
A Drees,
K A Drees,
J M Durham,
A Durum,
D Dutta,
S Edwards,
Y V Efremenko,
F Ellinghaus,
T Engelmore,
A Enokizono,
H En'yo,
S Esumi,
B Fadem,
D E Fields,
M Finger,
M Finger Jr,
F Fleuret,
S L Fokin,
Z Fraenkel,
J E Frantz,
A Franz,
A D Frawley,
K Fujiwara,
Y Fukao,
T Fusayasu,
I Garishvili,
A Glenn,
H Gong,
M Gonin,
Y Goto,
R Granier de Cassagnac,
N Grau,
S V Greene,
M Grosse Perdekamp,
T Gunji,
H-Å Gustafsson,
J S Haggerty,
K I Hahn,
H Hamagaki,
J Hamblen,
R Han,
J Hanks,
E P Hartouni,
E Haslum,
R Hayano,
X He,
M Heffner,
T K Hemmick,
T Hester,
J C Hill,
M Hohlmann,
W Holzmann,
K Homma,
B Hong,
T Horaguchi,
D Hornback,
S Huang,
T Ichihara,
R Ichimiya,
J Ide,
Y Ikeda,
K Imai,
M Inaba,
D Isenhower,
M Ishihara,
T Isobe,
M Issah,
A Isupov,
D Ivanischev,
B V Jacak,
J Jia,
J Jin,
B M Johnson,
K S Joo,
D Jouan,
D S Jumper,
F Kajihara,
S Kametani,
N Kamihara,
J Kamin,
J H Kang,
J Kapustinsky,
K Karatsu,
D Kawall,
M Kawashima,
A V Kazantsev,
T Kempel,
A Khanzadeev,
K M Kijima,
B I Kim,
D H Kim,
D J Kim,
E Kim,
E J Kim,
S H Kim,
Y J Kim,
E Kinney,
K Kiriluk,
A Kiss,
E Kistenev,
L Kochenda,
B Komkov,
M Konno,
J Koster,
D Kotchetkov,
A Kozlov,
A Král,
A Kravitz,
G J Kunde,
K Kurita,
M Kurosawa,
Y Kwon,
G S Kyle,
R Lacey,
Y S Lai,
J G Lajoie,
A Lebedev,
D M Lee,
J Lee,
K Lee,
K B Lee,
K S Lee,
M J Leitch,
M A L Leite,
E Leitner,
B Lenzi,
X Li,
P Liebing,
L A Linden Levy,
T Liška,
A Litvinenko,
H Liu,
M X Liu,
B Love,
R Luechtenborg,
D Lynch,
C F Maguire,
Y I Makdisi,
A Malakhov,
M D Malik,
V I Manko,
E Mannel,
Y Mao,
H Masui,
F Matathias,
M McCumber,
P L McGaughey,
N Means,
B Meredith,
Y Miake,
A C Mignerey,
P Mikeš,
K Miki,
A Milov,
M Mishra,
J T Mitchell,
A K Mohanty,
Y Morino,
A Morreale,
D P Morrison,
T V Moukhanova,
J Murata,
S Nagamiya,
J L Nagle,
M Naglis,
M I Nagy,
I Nakagawa,
Y Nakamiya,
T Nakamura,
K Nakano,
J Newby,
M Nguyen,
R Nouicer,
A S Nyanin,
E O'Brien,
S X Oda,
C A Ogilvie,
M Oka,
K Okada,
Y Onuki,
A Oskarsson,
M Ouchida,
K Ozawa,
R Pak,
V Pantuev,
V Papavassiliou,
I H Park,
J Park,
S K Park,
W J Park,
S F Pate,
H Pei,
J-C Peng,
H Pereira,
V Peresedov,
D Yu Peressounko,
C Pinkenburg,
R P Pisani,
M Proissl,
M L Purschke,
A K Purwar,
H Qu,
J Rak,
A Rakotozafindrabe,
I Ravinovich,
K F Read,
K Reygers,
V Riabov,
Y Riabov,
E Richardson,
D Roach,
G Roche,
S D Rolnick,
M Rosati,
C A Rosen,
S S E Rosendahl,
P Rosnet,
P Rukoyatkin,
P Ružička,
B Sahlmueller,
N Saito,
T Sakaguchi,
K Sakashita,
V Samsonov,
S Sano,
T Sato,
S Sawada,
K Sedgwick,
J Seele,
R Seidl,
A Yu Semenov,
R Seto,
D Sharma,
I Shein,
T-A Shibata,
K Shigaki,
M Shimomura,
K Shoji,
P Shukla,
A Sickles,
C L Silva,
D Silvermyr,
C Silvestre,
K S Sim,
B K Singh,
C P Singh,
V Singh,
M Slunečka,
R A Soltz,
W E Sondheim,
S P Sorensen,
I V Sourikova,
N A Sparks,
P W Stankus,
E Stenlund,
S P Stoll,
T Sugitate,
A Sukhanov,
J Sziklai,
E M Takagui,
A Taketani,
R Tanabe,
Y Tanaka,
K Tanida,
M J Tannenbaum,
S Tarafdar,
A Taranenko,
P Tarján,
H Themann,
T L Thomas,
M Togawa,
A Toia,
L Tomášek,
H Torii,
R S Towell,
I Tserruya,
Y Tsuchimoto,
C Vale,
H Valle,
H W van Hecke,
E Vazquez-Zambrano,
A Veicht,
J Velkovska,
R Vértesi,
A A Vinogradov,
M Virius,
V Vrba,
E Vznuzdaev,
X R Wang,
D Watanabe,
K Watanabe,
Y Watanabe,
F Wei,
R Wei,
J Wessels,
S N White,
D Winter,
J P Wood,
C L Woody,
R M Wright,
M Wysocki,
W Xie,
Y L Yamaguchi,
K Yamaura,
R Yang,
A Yanovich,
J Ying,
S Yokkaichi,
Z You,
G R Young,
I Younus,
I E Yushmanov,
W A Zajc,
C Zhang,
S Zhou,
L Zolin
University of Colorado, Boulder, Colorado 80309, USA.
Flow coefficients v_{n} for n=2, 3, 4, characterizing the anisotropic collective flow in Au+Au collisions at sqrt[s_{NN}]=200 GeV, are measured relative to event planes Ψ_{n}, determined at large rapidity. We report v_{n} as a function of transverse momentum and collision centrality, and study the correlations among the event planes of different order n. The v_{n} are well described by hydrodynamic models which employ a Glauber Monte Carlo initial state geometry with fluctuations, providing additional constraining power on the interplay between initial conditions and the effects of viscosity as the system evolves. This new constraint can serve to improve the precision of the extracted shear viscosity to entropy density ratio η/s.
J Investig Med. 2012 Jan 3;:
22222233
From the *Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK; †Neurological Institute, Cleveland Clinic, Cleveland, OH; and ‡Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK.
OBJECTIVE: To investigate the association of Clostridium difficile infection (CDI) with the outcomes of hospitalized patients with end-stage renal disease (ESRD). METHODS: We extracted all adult cases with a discharge diagnosis of ESRD or CDI from the United States Nationwide Inpatient Sample 2009 database. Outcome variables (mortality, length of hospital stay [LOS], and hospitalization charges), demographic information, and comorbidity data were collected. Data were evaluated by univariate and multiple regression analyses. RESULTS: We identified 184,139 cases with ESRD of which 2.8% had CDI. Comparison of patients with ESRD + CDI to those with only ESRD revealed in-hospital mortality (13.2% vs 5.3%; P < 0.001), LOS (17.3 vs 7.1 days; P < 0.001), and charges ($124,846 vs $56,663; P < 0.001) to be more than 2-fold greater. In the ESRD cohort (ESRD only and ESRD + CDI), CDI was independently associated with greater mortality (adjusted odds ratio, 2.15; 95% CI, 2.07-2.24; P < 0.001), longer LOS (mean difference, 9.4 days; 95% CI, 9.2-9.5; P < 0.001), and higher charges (mean difference,$62,824; 95% CI, 61,615-64,033; P < 0.001). CONCLUSIONS: Clostridium difficile infection is associated with significantly worse outcomes in hospitalized patients with ESRD.
|
Polish News | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|